Bayer Aktiengesellschaft (BAYRY) Stock Price, News & Analysis

Company Overview

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women's health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates. Its Consumer Health segment produces and markets nonprescription medicines and self-care products intended for a broad global audience. The Crop Science division supplies seeds, crop protection products and digital farming tools to farmers and agribusinesses, integrating agronomic services with chemical and seed portfolios to address productivity and sustainability challenges.

Key historical milestones include the company’s founding in the 19th century and substantial expansion through acquisitions, most notably the 2018 purchase of Monsanto, which significantly expanded Bayer’s seed and crop protection footprint. That acquisition also brought high-profile legal and regulatory matters related to glyphosate-based products, which have been a notable element of the company’s recent corporate history. Bayer conducts operations across Europe, the Americas, Asia-Pacific and other regions, with global manufacturing, research centers and commercial organizations.

Bayer is governed by a board of management and a supervisory board and invests heavily in research and development to sustain long-term product pipelines in health and agriculture. The company’s activities emphasize innovation, regulatory compliance and global market presence while navigating complex legal, environmental and commercial landscapes typical for a multinational life sciences firm.

Key Stats

• Today's Range: $11.08 to $11.23
• 50-Day Range: $10.54 to $12.12
• 52-Week Range: $6.90 to $14.85
• Volume: 1.26 million shs
• Average Volume: 1.66 million shs
• Market Capitalization: $43.66 billion
• P/E Ratio: N/A
• Dividend Yield: 0.18%
• Price Target: N/A
• Consensus Rating: Buy

Bayer Aktiengesellschaft Stock Analysis - MarketRank™

Bayer Aktiengesellschaft scored higher than 64% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Buy

Consensus Rating

Bayer Aktiengesellschaft has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 3 strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Bayer Aktiengesellschaft has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 7.20%

Earnings Growth

Earnings for Bayer Aktiengesellschaft are expected to grow by 7.20% in the coming year, from $1.25 to $1.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bayer Aktiengesellschaft is -17.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bayer Aktiengesellschaft is -17.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Bayer Aktiengesellschaft has a PEG Ratio of 3.54. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bayer Aktiengesellschaft has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Bayer Aktiengesellschaft has been sold short.

Short Interest Ratio / Days to Cover

Bayer Aktiengesellschaft has a short interest ratio ("days to cover") of 0.03, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bayer Aktiengesellschaft has recently decreased by 21.46%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Bayer Aktiengesellschaft has a dividend yield of 0.21%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Bayer Aktiengesellschaft does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Bayer Aktiengesellschaft will have a dividend payout ratio of 1.49% next year. This indicates that Bayer Aktiengesellschaft will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.60

News Sentiment

Bayer Aktiengesellschaft has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Bayer Aktiengesellschaft this week, compared to 7 articles on an average week.

Search Interest

4 people have searched for BAYRY on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Bayer Aktiengesellschaft to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bayer Aktiengesellschaft insiders have not sold or bought any company stock.

Percentage Held by Institutions

Bayer Aktiengesellschaft has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/25/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BAYRY
• CIK: 1144145
• Web: www.bayer.com
• Phone: 49214301
• Fax: 49-21-4306-6328
• Employees: 88,078
• Year Founded: 1863

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 8.89
• P/E Growth: 3.54
• Net Income: -$4.10 billion
• Net Margins: -4.75%
• Pretax Margin: -6.87%
• Return on Equity: 17.74%
• Return on Assets: 4.88%

Debt

• Debt-to-Equity Ratio: 1.22
• Current Ratio: 1.01
• Quick Ratio: 0.63

Sales & Book Value

• Annual Sales: $51.55 billion
• Price / Sales: 0.85
• Cash Flow: $2.18 per share
• Price / Cash Flow: 5.09
• Book Value: $7.50 per share
• Price / Book: 1.48

Miscellaneous

• Outstanding Shares: 3,930,000,000
• Free Float: N/A
• Market Cap: $43.66 billion
• Optionable: Not Optionable
• Beta: 0.62